2. Forward Looking Statement
Our commentary and responses to your questions may contain
forward-looking statements, including comments concerning
clinical trials and product development programs, evaluation of
potential opportunities, the level of corporate expenditures,
the assessment of Inovio’s technology by potential corporate
partners, capital market conditions, timing of events, cash
consumption and other subjects. Information concerning
factors that could cause actual results to differ materially from
those set forth in our Annual Report on Form 10-K for the year
ended December 31, 2012, our Form 10-Q for the quarter
ended September 30, 2013 and other regulatory filings from
time to time.
2
3. Roche Partnership
• Collaborating with a global leader in innovative cancer drugs
• Develop and commercialize Inovio’s prostate cancer (INO5150) and hepatitis B (INO-1800) immunotherapies
• $10 million up-front payment
• $412.5 million milestone payments for development and
commercial events
• Roche may pay other development milestone payments if it
pursues other indications with INO-5150 or INO-1800
• Roche to fund all ongoing development costs
• Up to double-digit royalties on sales of a marketed product
3
4. T cells: Inovio Commands the Body’s SWAT Team
Infected
cell
• Are safe and tolerable
• Requires a directive
to attack
T cell
Cytotoxic T lymphocyte
4
Provided by Dr. Philip Greenberg
Hutchinson Cancer Research Center
6. The Basis For How We Stimulate T-cells
Antigen Y
Select important
common antigen(s),
which body recognizes
as foreign and relates
to a cancer or infected
cell
Antigen Y
Strain 2
Antigen Y
Strain X
6
Strain 1
Choose important
strains/variants of
target virus/cancer
7. The Basis For How We Stimulate T-cells
Antigen Y
Antigen Y
Antigen Y
Strain 2
Strain X
Identify gene sequence
of selected antigen(s) from
chosen strains/variants of
the virus/cancer
Strain 1
Synthetically create optimal
consensus gene sequence for
the selected antigen
7
8. The Basis For How We Stimulate T-cells
Insert SynCon® gene
sequence for selected
antigen into DNA plasmid
Antigen
consensus
sequence
SYNCON®
DNA
SynCon DNA plasmid ready
to manufacture
8
DNA
Plasmid
9. The Basis For How We Stimulate T-cells
DNA vaccine delivered
into muscle or skin
Antibodies or killer T-cells that can eliminate
cancerous or infected cells are produced
9
Electroporation: millisecond
electrical fields applied
Antigen-presenting cells
engulf the antigens and carry
them to lymph nodes
Temporary pores in cell
membrane; significant cellular
uptake of vaccine
Cell membrane reseals. Cellular machinery uses
the DNA code to produce one or more of the
targeted disease antigens
11. #1 in Accelerating and Driving T Cell Responses
“Immunotherapy against
HPV 16/18 generates
potent TH1 and cytotoxic
cellular immune responses”
October 10, 2012
“Safety and comparative
immunogenicity of an HIV-1
DNA vaccine in combination
with plasmid Interleukin 12
and impact of intramuscular
electroporation for delivery”
July 8, 2013
11
12. Broad Medical and Market Opportunities
Product Name
Indication
Preclinical
Vgx-3100
Cervical dysplasia
Therapeutic
INO-3112
Cervical Cancer
Therapeutic
INO-3112
Head & Neck Cancer
Phase I
Therapeutic
Ino-5150
Prostate cancer
Ino-1400
Breast/lung cancers
pennvax®
hiv
Preventive/Therapeutic
Ino-3510
influenza
Preventive
Ino-8000
Hepatitis C
Therapeutic
ino-1800
Hepatitis B
Therapeutic
MaV-12
malaria
Preventive
12
INTERNALLY FUNDED
Therapeutic
Therapeutic
EXTERNALLY FUNDED
Phase II
Phase III
13. Inovio’s Lead Program
VGX 3100:
• Capitalizes on Inovio’s ability to generate T cells
• Immunotherapy for pre-cancers and cancers
caused by human papillomavirus (HPV)
• Phase II on-going: high grade cervical precancers (CIN 2/3 dysplasia)
• Projected efficacy data: mid-2014
13
15. VGX-3100: Phase I Study Data
Inovio’s Lead Program
• Strong T-cell response in 14 of
18 (78%) vaccinated subjects at
month 4
• 83% response rate in highest
dose group
15
*Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.
Sci Transl Med. 2012 Oct; 4:155ra13. dOI:10.1126/scitranslmed.3004414
16. Inovio’s Lead Program
Phase I trial results for vgx-3100
•
•
16
9 month durability of
robust T cell response
in 12/14 responders
• 10/11 responders
showed killing effect against
target cells
Safe & well tolerated
Source: Science Translational Medicine Oct. 2012
18. Broad Medical and Market Opportunities
HPV product
franchise planning
• CIN 2/3 Phase III
• Other HPV-related indications: initiate Phase IIs
• Orphan designation potential
18
19. Strategy
• Build on proof-ofconcept studies with
phase I/II clinical trials
• Spread cost/risk with:
o Non-dilutive
partner funding
o R&D grants
o “Sponsored”
clinical trials
• May partner or license
out products for
further development
and commercialization
19
20. Broad Base of Support for Inovio
•
•
•
•
Universities
Government
Foundations
Corporate partnerships
Almost $60M in funding since 2009
20
23. Management
J.Joseph Kim, PhD
President & CEO
• Decades of biotechnology/pharma
management
• Merck: hepatitis A and B vaccines
manufacturing; HIV vaccine (Ad5) R&D
Niranjan Y. Sardesai, PhD
COO
• Extensive biotech management and product
development experience
• Led development of diagnostics for
mesothelioma, bladder cancer, and ovarian
cancer for Fujirebio Diagnostics
23
Peter Kies
CFO
• Ernst & Young
• Experience with growth companies
anthrax
Louis Pasteur
Mark L. Bagarazzi, MD
CMO
• Clinical research experience incl. Merck
• Led clinical/regulatory for shingles and
rotavirus vaccines; DNA vaccine expert
24. Board of Directors
Morton Collins, PhD
Avtar Dhillon, MD
• General Partner, Battelle Ventures and
Innovations Valley Partners
Chairman, BOD
• Former President & CEO,
Inovio Biomedical
Simon X. Benito
• Former Senior Vice President,
Merck Vaccine Division
Angel Cabrera, PhD
• President, George Mason University
• Former President, Thunderbird School of
Global Management
24
anthrax
Louis Pasteur
J.Joseph Kim, PhD
• President & CEO, Inovio
Adel Mahmoud, PhD
• Professor, Princeton University
• Former President, Merck Vaccines
• Responsible for Gardasil®, Zostavax®,
Proquad® and Rotateq®
25. Scientific Advisory Board
Philip Greenberg, MD
David B. Weiner, PhD
• Expert in T-cell immunology
• Head, Immunology Program, Fred
Hutchinson Cancer Research Center
Chairman
•“Father of DNA vaccines”
• Dept. of Pathology & Laboratory Medicine,
University of Pennsylvania
Thomas S. Edgington, MD
• Founded multiple biotech companies;
extensively published
• Emeritus Professor, Scripps
Research Institute
Anthony W. Ford-Hutchinson, PhD
• Former SVP, Vaccines R&D, Merck
• Oversaw development: Singulair®, Januvia®,
Gardasil®, Zostavax®, Proquad® and Rotateq®
25
anthrax
Louis Pasteur
Stanley A. Plotkin, MD
• Developed rubella and rabies vaccines
• Oversaw Sanofi flu vaccine
• Emeritus Professor, Wistar Institute &
University of Pennsylvania
31. The Opportunity
Investor Highlights
• Break-through immune therapy with the power
to save lives and maximize shareholder value
• Targeting broad range of diseases and
billion dollar markets
• Best-in-class T cells to prevent, treat & cure
cancers and infectious diseases
• Phase II efficacy data coming
• Validating partnership with Roche
31
